Vericel (VCEL) Total Non-Current Liabilities (2010 - 2026)
Vericel's (VCEL) quarterly Total Non-Current Liabilities came in at $127.5 million in Q1 2026, little changed year-on-year from $127.3 million in Q1 2025, and down 2.98% quarter-over-quarter from $131.4 million in Q4 2025.
Vericel (VCEL) Total Non-Current Liabilities (2010 - 2026) Analysis & Trends
Vericel has disclosed Total Non-Current Liabilities across 17 years of filings, most recently posting $127.5 million for Q1 2026.
- Total Non-Current Liabilities for Q1 2026 came in at $127.5 million, changed 0.21% year-over-year; the trailing twelve-month figure through Mar 2026 was $127.5 million (changed 0.21% YoY), and the FY2025 annual result was $131.4 million, down 6.04% from the prior year.
- Total Non-Current Liabilities came in at $127.5 million for Q1 2026 at Vericel, down from $131.4 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $139.9 million in Q4 2024 to a low of $67.8 million in Q1 2022.
- The 5-year median for Total Non-Current Liabilities is $127.2 million (2025), against an average of $113.4 million.
- Across the five-year window, Total Non-Current Liabilities soared 61.98% in 2023 and retreated 6.04% in 2025, its largest moves.
- Vericel's Total Non-Current Liabilities stood at $80.7 million in 2022, then jumped by 58.06% to $127.6 million in 2023, then gained by 9.62% to $139.9 million in 2024, then slipped by 6.04% to $131.4 million in 2025, then retreated by 2.98% to $127.5 million in 2026.
- The last three Total Non-Current Liabilities figures came in at $127.5 million (Q1 2026), $131.4 million (Q4 2025), and $129.7 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 42,980.09 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 11.03 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 95.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 5.87 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 64.76 Mn |
| 10 | Vericel | 2.04 Bn | 1.90 Bn | 49.27 Mn | 127.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 127.52 Mn |
| Dec 31, 2025 | 131.43 Mn |
| Sep 30, 2025 | 129.74 Mn |
| Jun 30, 2025 | 127.14 Mn |
| Mar 31, 2025 | 127.25 Mn |
| Dec 31, 2024 | 139.88 Mn |
| Sep 30, 2024 | 132.69 Mn |
| Jun 30, 2024 | 133.66 Mn |
| Mar 31, 2024 | 122.61 Mn |
| Dec 31, 2023 | 127.61 Mn |
| Sep 30, 2023 | 113.68 Mn |
| Jun 30, 2023 | 111.76 Mn |
| Dec 31, 2022 | 80.73 Mn |
| Sep 30, 2022 | 70.18 Mn |
| Jun 30, 2022 | 69.98 Mn |
| Mar 31, 2022 | 67.78 Mn |
| Dec 31, 2021 | 73.20 Mn |
| Sep 30, 2021 | 67.32 Mn |
| Jun 30, 2021 | 70.79 Mn |
| Mar 31, 2021 | 71.20 Mn |